Denali Therapeutics is a American biotechnology company headquartered in South San Francisco, California, founded in 2013 as a spin-off from Biogen. The company is focused exclusively on developing therapies for neurodegenerative diseases, with a particular emphasis on [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease). Denali's proprietary platform technologies include the Transport Vehicle (TV) platform for enhanced brain delivery of biologics[@denali2024].
History and Evolution
Denali was founded in 2013 by scientists from Biogen, including Dr. Ryan Watts and Dr. Alex Schuth, with a mission to develop breakthrough therapies for neurodegenerative diseases. The company went public in 2017[@denali2024].
Key milestones:
2013: Founded as Biogen spin-off
2017: IPO on NASDAQ
2021: First Phase 3 initiation (DNL593 for ALS)
2023: Partnership expansion with Biogen for TV platform[@denali2024]
Pipeline Overview
Denali has one of the most robust neurodegenerative disease pipelines in biotech, with programs across Alzheimer's disease, Parkinson's disease, ALS, and Frontotemporal Dementia.
Funding
IPO: 2021 (NASDAQ: DNLI)
Market Cap: ~$1B (2026)
Funding History: Series A-F (~00M+), IPO
Partnerships: Biogen, Sanofi
Pipeline Visualization
```mermaid gantt title Denali Therapeutics Pipeline dateFormat YYYY axisFormat %Y
...
Overview
Denali Therapeutics is a American biotechnology company headquartered in South San Francisco, California, founded in 2013 as a spin-off from Biogen. The company is focused exclusively on developing therapies for neurodegenerative diseases, with a particular emphasis on [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease). Denali's proprietary platform technologies include the Transport Vehicle (TV) platform for enhanced brain delivery of biologics[@denali2024].
History and Evolution
Denali was founded in 2013 by scientists from Biogen, including Dr. Ryan Watts and Dr. Alex Schuth, with a mission to develop breakthrough therapies for neurodegenerative diseases. The company went public in 2017[@denali2024].
Key milestones:
2013: Founded as Biogen spin-off
2017: IPO on NASDAQ
2021: First Phase 3 initiation (DNL593 for ALS)
2023: Partnership expansion with Biogen for TV platform[@denali2024]
Pipeline Overview
Denali has one of the most robust neurodegenerative disease pipelines in biotech, with programs across Alzheimer's disease, Parkinson's disease, ALS, and Frontotemporal Dementia.
Funding
IPO: 2021 (NASDAQ: DNLI)
Market Cap: ~$1B (2026)
Funding History: Series A-F (~00M+), IPO
Partnerships: Biogen, Sanofi
Pipeline Visualization
Mermaid diagram (expand to render)
Key Programs
DNL310 (Eternity)
DNL310 is an enzyme replacement therapy for mucopolysaccharidosis II (Hunter syndrome) using Denali's Transport Vehicle platform. Not directly AD/PD but demonstrates TV platform capability[@denali2024].
DNL151 (LRRK2 Inhibitor)
DNL151 is a small molecule [LRRK2](/entities/lrrk2) kinase inhibitor being developed for Parkinson's disease. LRRK2 mutations are the most common genetic cause of familial PD. The program has completed Phase 1 and advanced to Phase 2[@denali2024a].
DNL126 (TREM2 Activator)
DNL126 is an antibody designed to activate [TREM2](/proteins/trem2), a receptor on [microglia](/cell-types/microglia-neuroinflammation) that plays a critical role in the brain's immune response to [amyloid](/proteins/amyloid-beta) plaques. TREM2 variants are significant genetic risk factors for Alzheimer's disease[@schwartzentruber2011].
DNL593 (ATV:PGRN)
DNL593 is an ATV ([ApoE](/proteins/apoe) Transfer Vehicle):PGRN (progranulin) fusion protein being developed for ALS and Frontotemporal Dementia. Progranulin deficiency is linked to these conditions[@baker2006].
Technology Platform
Transport Vehicle (TV) Platform
Denali's proprietary Transport Vehicle platform enables enhanced delivery of therapeutics across the [blood-brain barrier](/entities/blood-brain-barrier) (BBB). The TV platform uses a receptor-mediated transcytosis approach to transport large molecules into the brain[@denali2024].
Partnerships
Biogen Partnership
Denali partnered with Biogen in 2020 to develop therapeutics using the Transport Vehicle platform for neurological diseases. This partnership has provided significant funding and expertise[@denali2024].
Sanofi Partnership
Denali has partnered with Sanofi for certain programs in neurodegeneration[@denali2024].